Vaxil is a cutting edge Israeli biotech focused on immuno-oncology, with a portfolio of IP including its primary immunotherapy ImMucin™ and Vaxil™ has shown very unique results in its clinical trials, targeted immune responses rapidly upon treatment
Vaxil is a cutting edge Israeli biotech focused on immuno-oncology, with a portfolio of IP including its primary immunotherapy ImMucin™ and Vaxil™ has shown very unique results in its clinical trials, targeted immune responses rapidly upon treatment